Meeting
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
Authors
Yago Nieto
The University of Texas MD Anderson Cancer Center, Houston, TX
Yago Nieto , Shi-Ming Tu , Matthew T. Campbell , Roland Bassett , Nizar M. Tannir , John Francis Ward , Wayne Lewis Hofstetter , Roy B. Jones , Borje Andersson , Alison M Gulbis , Celina Ledesma , Melissa Timmons , Michelle Trapp , Richard E. Champlin , Lance C. Pagliaro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
NCT00936936
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4519)
DOI
10.1200/JCO.2017.35.15_suppl.4519
Abstract #
4519
Poster Bd #
197
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa
Poster
2011 ASCO Annual Meeting
Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT).
First Author: A. Jain